Cohance Lifesciences
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Cohance Lifesciences - overview
Established
2003
Location
Hyderabad, Telangana, India
Primary Industry
Pharmaceuticals
About
Based in Telangana, India, and founded in 2003, Cohance Lifesciences operates as a pharmaceutical manufacturing company. In February 2024, Cohance Lifesciences and Suven Pharmaceuticals Ltd. , portfolio companies of Advent International agreed to merge. The firm as of March 2024, operates 7 manufacturing sites with a reactor capacity of over 1,200 KL, serving customers across nearly 60 countries, and is led by its Managing Director and CEO, Prasada Raju.
The company provide of end-to-end solutions in the pharmaceutical industry, specializing in Contract Development and Manufacturing Organization (CDMO) services, API and Formulations, and Clinical Research and Bio Analytical Studies. Cohance Lifesciences’ product basket has more than 80 molecules including Betahistine, Drotaverine, Entacapone, Fluvoxamine, Lamotrigine, Mebeverine, Midazolam and Quetiapine. Additionally, the firm’s Clinical and Analytical Services division delivers outcomes in Bioavailability & Bioequivalence studies and Clinical Trials. The February 2024 acquisition will support both Cohance Lifesciences and Suven Pharmaceuticals Limited to build an end-to-end contract development and manufacturing organisation (CDMO) and merchant active pharmaceutical ingredient (API) player servicing the pharmaceutical and specialty chemical markets.
Primary Industry
Pharmaceuticals
Sub Industries
Medical Supplies, Pharmaceutical Research & Development, Specialty Pharmaceuticals
Website
www.cohance.com
Verticals
Manufacturing
Company Stage
Add-on
Total Amount Raised
Subscriber access only
Cohance Lifesciences - deals
| Deals Type | Deal Status | Target (s) | Deal Date | Investor(s) | Seller(s) | Deal size (Mn) | Enterprise value (Mn) | Post-money valuation (Mn) | EBITDA multiple (x) | Revenue multiple (x) | Lead partner (s) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Add-on | Announced | Cohance Lifesciences | - | ||||||||
| Add-on | Completed | Avra Laboratories Pvt. Ltd. | - | ||||||||
| Add-on, Trade Sale | Completed | ZCL Chemicals Limited | - | ||||||||
| Add-on | Completed | RA Chem Pharma Limited | - |
Displaying 1 - 4 of 4
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.